Amy N. Courtney
0000-0001-7013-3042
Publication & Citation Trends
Publications
0 total
Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cells.
Cited by 0
Semantic Scholar
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
Cited by 2
Semantic Scholar
Abstract 4012: Triple disruption of CCDC6, CBLB, and ASB2 promotes the therapeutic efficacy of Glypican 3 targeted T cells
Cited by 0
Semantic Scholar
Response to: Correspondence on “Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15” by Ataca Atilla and Atilla OA
Cited by 0
Semantic Scholar
553 A phase I clinical trial of allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B cell malignancies: an interim analysis
Cited by 0
Semantic Scholar
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function
Cited by 0
Semantic Scholar
216 Development of rejection resistant allogeneic CAR-NKT cell therapy for CD19-positive B cell malignancies
Cited by 0
Semantic Scholar
Research Topics
Immune Cell Function and Interaction
(82)
CAR-T cell therapy research
(48)
Neuroblastoma Research and Treatments
(44)
T-cell and B-cell Immunology
(23)
Immunotherapy and Immune Responses
(8)
Affiliations
Maine Medical Center
The University of Texas MD Anderson Cancer Center
Baylor University
MRC Laboratory of Molecular Biology
Baylor College of Medicine